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Abstract 
Objectives: The aims of this study were: 1, to investigate the association between the 
rs4680 Val158Met polymorphism in frequent episodic (FETTH) and chronic (CTTH) 
tension-type headache; and 2, to analyse the association between the rs4680 Val158Met 
polymorphism with clinical, psychological, or psychophysical variables. Methods: Fifty 
women with FETTH, 50 with CTTH, and 50 matched healthy women participated. 
After amplifying Val158Met polymorphism by polymerase chain reaction, the genotype 
frequencies and allele distributions based on restriction fragment length polymorphism 
were assessed. Participants were classified according to the Val158Met polymorphism 
rs4680 genotype (Val/Val, Val/Met, or Met/Met). A headache diary collected clinical 
features. Disability (Headache Disability Inventory), sleep quality (Pittsburgh Sleep 
Quality Index), and depression/anxiety levels (Hospital Anxiety and Depression Scale) 
were also assessed. Pressure pain thresholds (PPT) were assessed bilaterally over the 
temporalis, upper trapezius, second metacarpal, and tibialis anterior by a blinded 
assessor. Results: The distribution of rs4680 Val158Met genotype was not significantly 
different between women with/without headache (P=0.796). No differences in headache 
features, disability, anxiety, and sleep quality were observed depending on the rs4680 
Val158Met genotype. Women with CTTH, but not FETTH, carrying the Met/Met 
genotype had lower widespread PPTs and higher depressive symptoms than those with 
Val/Val or Val/Met genotype (P<0.05). Conclusion: The Val158Met polymorphism 
(rs4680) does not appear to be involved in predisposition to suffer from tension-type 
headache; however, this genetic factor may be involved in the pathogenesis expression 
of CTTH, as greater pressure pain sensitivity and higher depressive levels were found in 
CTTH carrying the Met/Met genotype.  
Key word: Catechol-O-methyltransferase gene, tension-type headache, pressure pain.  
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Introduction 
 Tension type headache (TTH) is the most common headache disorder with a 
global annual prevalence of 42% in the general population.
1 
In the last Global Burden of 
Disease Study, headache (mostly including TTH and migraine) was found to be the 
second most prevalent pain condition in the world.
2 
Similarly, the general costs of 
headache, most related to migraine and TTH, in Europe in 2010 were €13.8 billion.
3
  
Although the pathophysiology of this condition is not completely understood, it 
seems clear that individuals with TTH exhibit an altered nociceptive pain processing.
4 
There are several factors that could affect the pain processing in humans. One of these 
factors is genetics. Some genetic epidemiological studies have investigated the familial 
aggregation in some headaches. In fact, a hereditary component seems to be clear in 
migraine;
5,6
 however, this topic has been less investigated in TTH, and mostly focused 
in the chronic form. For instance, first-degree relatives of patients with chronic tension 
type headache (CTTH) had a 3.1-fold increased risk also of experiencing CTTH.
7,8
  
       The catechol-O-methyltransferase (COMT) gene is considered one potential genetic 
determinant in chronic pain syndromes.
9 
The COMT is an enzyme generally involved in 
the metabolic degradation of several neurotransmitters, e.g., dopamine, norepinephrine, 
or epinephrine.
10 
The activity of the COMT gene is affected by different polymorphisms 
(i.e., rs4680, rs6269, rs4633, or rs4818), being the rs4680 the COMT polymorphism the 
most investigated in the literature in relation to chronic pain.
9 
It has been observed that 
the rs4680 genetic polymorphism due to a G→A substitution at codon 158 of this gene, 
leading to a valine (Val) to methionine (Met) substitution, results in different COMT 
gene activity related to pain sensitivity. In fact, a valine (Val) at codon 158 results in a 
heat-stable, high-activity variant (Val/Val), whereas a methionine (Met) at the same 
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position (Val/Met or Met/Met) results in heat-labile, low-activity variants.
11 
It has been 
found that subjects with Met/Met genotype exhibit higher pain sensitivity
12,13 
and 
different brain responses to painful stimuli
14 
than those with the Val/Val genotype, 
supporting that this polymorphism could play a relevant role in nociceptive processing. 
Although the COMT gene may have a potential role in the development of some 
chronic pain conditions, particularly fibromyalgia syndrome, its role in localized pain 
syndromes, such as headaches, is controversial.
15
 In fact, most studies investigating the 
role of the Val158Met polymorphism in primary headaches have been conducted in 
migraine. Few published studies have investigated the role of Val158Met polymorphism 
in patients with episodic and chronic TTH.
16,17
 Previous studies did not find significant 
differences in the distribution of the Val158Met polymorphism between subjects with 
TTH and healthy controls.
16,17
 Similarly, a study in children with CTTH did not also 
find significant differences in the distribution of the Val158Met polymorphism between 
children with or without CTTH.
18
 Therefore, based on current results the Val158Met 
polymorphism (rs4680) seems to be not associated to a higher risk of developing TTH; 
however, most previous studies included adults with episodic, but not chronic, TTH.  
      Although no significant differences in Val158Met polymorphism distribution would 
exist between individuals with and without TTH, there is evidence suggesting a genetic 
influence of this polymorphism in several clinical and neuro-physiological variables on 
different pain conditions, e.g., related-fatigue and localized pressure pain sensitivity in 
breast cancer survivors,
19 
or mood disorders in fibromyalgia syndrome.
20 
Therefore, it 
would be possible that the rs4680 Val158Met polymorphism could potentially influence 
some aspects of nociceptive processing in TTH. There is evidence supporting an hyper-
excitability of the central nervous system in individuals with TTH.
4
 This excitability of 
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the nervous system is characterized by hyperalgesia to different noxious stimuli, e.g., 
thermal, pressure, electrical. Some meta-analyses have observed that primary headaches 
mostly TTH and migraine, exhibit hyperalgesia to pressure pain as their main clinical 
manifestation of central sensitization.
21,22 
Additionally, it sems that emotional factors 
may also influence central nervous system excitability found in individuals with TTH. 
Among these factors, depression, anxiety, and sleep disorders can play a relevant role in 
the sensitization process since they are able of triggering hyperalgesic responses.
23 
The 
only study investigating the role of the Val158Met polymorphism in pain processing in 
primary headaches was conducted in children and found that children with CTTH with 
the Met/Met genotype showed higher pressure pain sensitivity than children carrying 
the Val/Val or the Val/Met genotype.
18
 No study has previously investigated the role of 
rs4680 Val158Met polymorphism in the phenotypic expression and altered nociceptive 
processing in adults with TTH.  
The aims of the current study were: 1) to evaluate the association between the 
rs4680 Val158Met polymorphism in adults with frequent episodic (FETTH) or CTTH; 
and 2) to analyze the association between the rs4680 Val158Met polymorphism with 
clinical, psychological and psychophysical variables (sensitivity to pressure pain) in 
adults with FETTH or CTTH. The hypotheses of this study were: 1, the presence of the 
rs4680 Val158Met polymorphism will be associated with CTTH, but not FETTH; 2, the 
presence of the Met/Met allele will be associated with worse clinical, psychological and 
psychophysical variables in both FETTH and CTTH. 
Methods 
Participants 
     Consecutive individuals with headache recruited from an university-based hospital 
between January 2016 and January 2018 were screened for possible eligibility criteria. 
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Tension type headache was diagnosed according to the International Classification of 
Headache Disorders criteria, third edition (ICHD3 beta 2013) down to third-digit level 
(code 2.2, 2.3) by a neurologist expert in headache.
24 
The neurologist performed a face-
to-face interview followed by a neurological examination. To be included, participants 
had to describe typical pain features of TTH including bilateral location, pressing and 
tightening pain, moderate-intense intensity, and no aggravation of pain during physical 
activity. In participants with high frequency of attacks, no more than 5 days/month with 
headache could meet criteria for migraine.
24
 Participants were excluded if presented: 1, 
other primary/secondary headache; 2, medication overuse headache as defined by the 
ICHD-III;
24
 3, history of neck or head trauma; 4, pregnancy; 5, cervical herniated disk; 
6, any systemic degenerative disease; 7, fibromyalgia syndrome; 8, receiving any 
treatment including anesthetic blocks, botulinum toxin or physical therapy within the 
previous 6 months; or, 9, male gender.  
Age-matched healthy subjects without history of headache diagnosis and without 
reporting a headache pain attack the previous year were also included. Exclusion criteria 
for the control group was the same as for the headache group. All participants read and 
signed the written consent form prior to their inclusion in the study. The local Ethics 
Committee of the Universidad Rey Juan Carlos (URJC 23/2015) approved the study. 
DNA Collection and COMT Genotyping 
          Non-stimulated whole saliva samples were collected into collection tubes (passive 
drooling technique) according to standardized procedures.
 
Saliva collections were made 
with participants seated and relaxed and between 9-11 am on days when were they were 
headache-free, or with a headache intensity of less than 3 points (in those patients with 
high frequency of attacks). Participants were asked not to eat or drink or chew gum for 
1 hour before the collection. Immediately after collection, samples were centrifuged at 
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3000 rpm for 15min to obtain the cell sediment and they were stored at -20º C until the 
analysis. We prefer to use saliva instead of blood sampling because salivary collection 
is a non-invasive, stress-free, and ethic suitable assessment method. 
Laboratory technicians were blinded to the subject’s condition. Genomic DNA 
was hence extracted from saliva cell sediments using the “Genomic DNA extraction and 
purification Kit” (Real Molecular Biology) following the manufacturer instructions. The 
single Val158Met (rs4680) nucleotide polymorphism was genotyped using a TaqMan® 
Drug Metabolism Genotyping Assays on a Real Time PCR ABI Prism 7000 Sequence 
Detection System (APPLIED BIOSYSTEM, USA) in the Genomic Unit at the Centro 
de Apoyo Tecnológico Universidad Rey Juan Carlos, Madrid (Spain). The 3 possible 
halotypes were associated with different fluorescent dyes to proper identification of the 
different genotype forms: Val/Val (H/H), Val/Met (H/L), or Met/Met (L/L). The results 
are derived from a G→A substitution at the following sequence:  
CCAGCGGATGGTGGATTTCGCTGGC [A/G] TGAAGGACAAGGTGTGCATGCCTGA 
Headache Clinical Features 
          A 4-weeks headache diary was used to register clinical features of the headache.
25 
The headache diary was used to calculate the following variables: 1) headache intensity, 
calculated from the mean intensity of the days with headache as assessed with a 11-
points numerical pain rate scale
26 
(NPRS; 0: no pain, 10: maximum pain); 2) headache 
frequency, calculated by dividing the number of days with headache by the number of 
weeks (days/week); and 3) headache duration, calculated by dividing the total hours of 
headache by the number of days with headache (hours/day). 
Psychological and Disability Variables 
The Hospital Anxiety and Depression Scale (HADS) was used to evaluate the 
levels of anxiety and depression. This questionnaire includes 7-items scored at a 4-
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
points scale for assessing anxiety (HADS-A) and other 7-items for assessing depressive 
(HADS-D) symptoms.
27 
Both subscales are considered reliable and valid for assessing 
anxiety (Cronbach's α: 0.83) and depression (Cronbach's α: 0.82).
28 
In individuals with 
headache, the HADS has shown good internal consistency (Cronbach's α: 0.83-0.84).
29 
 
The Headache Disability Inventory (HDI) was designed to assess the burden of 
headache using 25 items inquiring about the perceived impact of headache on emotional 
(HDI-E, 13-items, score 0-52) or physical (HDI-P, 12-items, score 0-48) functioning.
30 
A greater score suggests a greater burden or related-disability of headache. The HDI has 
exhibited good short (HDI-E: 0.93, HDI-P: 0.95) and long (HID-E:0.76, HDI-P: 0.83) 
stability.
31 
 
           The Pittsburgh Sleep Quality Index (PSQI) was used for
 
evaluating the quality of 
sleep over a 1-month period by including 19 self-perceived questions and 5 questions 
answered by bed or roommates.
32 
Item use varying response categories recording usual 
bed time, usual wake time, number of actual hours slept and number of minutes to fall 
asleep. Score from all answers is transformed into a global score (0-21) where a higher 
score indicates worse sleep quality.
33 
The PSQI has shown good internal consistency 
and test-retest reliability.
34  
Psychophysical Variables 
It seems that the main manifestation of the altered pain processing in individuals 
with TTH is the presence of sensitivity to pressure pain.
4
 It is generally considered that 
pressure hyperalgesia in painful areas, e.g., those related to trigemino-cervical nucleus 
caudalis, is more associated to localized sensitization; whereas the presence of pressure 
hyperalgesia in distant pain-free areas, i.e., lower extremity, is associated to widespread 
central sensitization.  
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Pressure pain thresholds (PPTs), i.e., the minimal amount of pressure where a 
sensation of pressure first changes to pain,
35 
were assessed with an electronic algometer 
(Somedic AB, Farsta, Sweden). The pressure was applied perpendicularly to the point at 
an approximately rate of 30 kPa/s via a 1cm
2
 probe. Participants were instructed to press 
the “stop button” of the algometer when the sensation first changed from pressure to 
pain. The mean of 3 trials on each point was calculated and used for the main analysis. 
A 30sec resting period was allowed between trials for avoiding temporal summation.
36 
The reliability of pressure algometry has been found to be high.
37,38 
The evaluation was held when patients were headache-free or, in those with high 
frequency of headache, it was permitted when the headache intensity was less than 3/10 
points on a NPRS. Only 5% of the patients experienced pain during PPTs assessment. 
Participants were asked to avoid any analgesic or muscle relaxant 24 hours prior to the 
examination. No change was made on the prophylactic treatment of the patients. All the 
participants attended a session for familiarization with the pressure test procedure over 
the wrist extensor muscles.  
           To determine pressure pain sensitivity at localized and remote (or non-localized), 
PPTs were bilaterally assessed over the temporalis muscle (i.e. trigeminal point), C5/C6 
zygapophyseal joint (i.e. extra-trigeminal point), the second metacarpal and the tibialis 
anterior muscle (i.e. distant pain-free points) by an assessor blinded to the individual’s 
condition. The order of assessment was randomized between participants. Since no side-
to-side differences were observed, mean of both sides were used in the analysis. 
Sample Size Calculation 
    Sample size determination and calculations were based on detecting a moderate-large 
effect size of 0.7 on PPTs between TTH and healthy controls accordingly to Val158Met 
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polymorphism distribution , a 2-tailed test, with an alpha level (α) of 0.05, and a desired 
power (β) of 90%. This generated a sample size of, at least, 42 participants per group.  
Statistical Analysis 
Data were analyzed with the SPSS statistical package (22.0 Version). Results are 
expressed as mean and 95% confidence interval (95% CI). The Kolmogorov-Smirnov 
test showed that all quantitative variables showed a normal distribution of the data (P > 
0.05). Comparisons of genotype distribution and allele frequency among groups were 
performed on raw frequencies using an extended chi-squared test (
2
). A 
2
 analysis of 
the Hardy-Weinberg equilibrium for the genotypes was conducted to determine whether 
the allele frequencies were stable within all groups. A 2x2 analysis of variance ANOVA 
was used to compare clinical and psychological outcomes according to the Val158Met 
polymorphism genotype (Val/Val, Val/Met, Met/Met) in women with headache (FETTH, 
CTTH). A 3x3 ANOVA test was used to investigate differences in PPTs over each point 
(temporalis, C5-C6 zygapophyseal joint, second metacarpal, tibialis anterior) according 
to the Val158Met polymorphism genotype (Val/Val, Val/Met, Met/Met) and by group 
(FETTH, CTTH, or controls). Post-hoc analyses comparisons were conducted with the 
Tukey test. The standardized mean difference (SMD: between-group differences/pooled 
standard deviation) to enable comparison of effect sizes in those variables significantly 
different between groups accordingly to Val158Met polymorphism distribution. Values 
were considered as trivial when range from 0.0 to 0.2, small from 0.2 to 0.49, moderate 
from 0.5 to 0.79, and large when greater than 0.8. The statistical analysis was conducted 
at a 95% confidence level, and a P value < 0.05 was considered statistically significant. 
Results 
One hundred and thirty (n=130) consecutive women presenting with headaches 
between January 2016 and 2018 were screened for eligibility criteria. Thirty (23%) were 
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excluded for the following reasons: migraine (n=14), previous whiplash (n=6), hemi-
cranial headache (n=5), and pregnancy (n=5). Finally, 50 women with CTTH (mean 
age: 4711 years), 50 with FETTH (mean age: 4810 years) satisfied all criteria, signed 
the informed consent and agreed to participate. Further, 50 age-matched women without 
headache (mean: 4811 years old) were also included. Table 1 summarizes clinical, 
psychological and psychophysical data of the sample. Women with CTTH exhibited 
significant longer headache duration (P=0.045), higher headache frequency (P<0.001), 
higher physical (P=0.04) or emotional (P=0.01) burden of headache, and higher levels 
of depression (P=0.007) than those with FETTH. Similarly, women with CTTH and 
FETTH exhibited higher widespread pressure pain sensitivity (P<0.001) as compared 
with healthy women, without differences between them (P>0.9). 
Distribution of rs4680 Val158Met Polymorphism in the COMT gene  
The genotype distribution in women with and without headache did not deviate 
from those expected based on the Hardy-Weinberg equilibrium. The distribution of the 
Val158Met rs4680 genotypes (2=1.670; P=0.796) or alleles (2=0.880; P=0.644) was 
not significantly different between women with TTH and healthy women (table 2).  
Clinical and psychological measures and rs4680 Val158Met Polymorphism  
 The mixed-model ANOVA did not reveal significant differences depending on 
the Val158Met polymorphism genotype (table 3) in both headache groups for years 
with headache (F=0.224; P=0.800), headache intensity (F=0.572; P=0.566), headache 
frequency (F=0.134; P=0.875) and headache duration (F=0.030; P=0.970). Additionally, 
no significant differences in prophylactic medication intake were found depending on 
the Val158Met polymorphism genotype (P=0.764). 
Similarly, no significant differences depending on the Val158Met polymorphism 
genotype were either found (table 4) in both women with FETTH and CTTH for HDI-P 
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(F=1.026; P=0.362), HDI-E (F=0.548; P=0.580), PSQI (F=0.814; P=0.446), or HADS-
A (F=1.529; P=0.199). A significant group * Val158Met genotype interaction (F=3.352; 
P=0.03) was observed for HADS-D: women with CTTH, but not those with FETTH, 
carrying the Met/Met genotype exhibited higher depressive levels than those with the 
Val/ Val (P=0.01; SMD: 1.01) or Val/Met (P=0.045; SMD: 0.51) genotype. 
Pressure pain sensitivity and rs4680 Val158Met polymorphism  
   The 3x3 mixed-model ANOVA revealed significant group*Val158Met polymorphism 
genotype interactions for PPTs over all points (temporalis: F=3.887, P= 0.023; C5-C6 
zygapophyseal joint: F=4.306, P=0.02; second metacarpal: F=4.492, P=0.018; tibialis 
anterior: F=4.656, P=0.015). Women with CTTH, but not with FETTH, carrying the 
Met/Met genotype showed significant (P<0.01) lower PPTs (i.e., greater pressure pain 
sensitivity) at localized and remote (or non-localized) sites than the women with CTTH 
carrying the Val/Met (0.62<SMD< 0.83) or Val/Val genotype (0.82<SMD<1.05). No 
significant differences in PPTs were observed between women with CTTH carrying the 
Val/Val or Val/Met genotype (P>0.8). Table 5 shows PPT according to Val158Met 
polymorphism genotype in women with FETTH, CTTH and healthy women.  
Discussion 
The current study did not find differences in the genotype distribution and allele 
frequency of the rs4680 Val158Met polymorphism among women with CTTH, FETTH 
and healthy women. Additionally, the presence of the Met/Met genotype was associated 
to greater pressure pain hyperalgesia at localized and remote (or non-localized) sites and 
depressive symptoms in women with CTTH, but not in those with FETTH or healthy 
controls. No association between the rs4680 Val158Met polymorphism and clinical or 
psychological variables was either found.  
rs4680 Val158Met polymorphism in tension-type headache 
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     No significant differences were observed in the distribution of the rs4680 Val158Met 
polymorphism between patients and healthy controls, supporting the assumption that 
this polymorphism does not appear to be involved in predisposition to suffer from TTH. 
Current results are similar to those previously reported in adults
16,17
 and children
18 
with 
CTTH. Our study is the first reporting the lack of this association in individuals with 
FETTH. In accordance with our results, the Val158Met polymorphism (rs4680) has not 
been associated with neuropathic pain,
39 
widespread pain,
40 
or musculoskeletal pain.
41 
Similarly, the rs4680 Val158Met polymorphism has not been either associated to the 
presence of migraine.
42 
The current results are supported by Takigawa et al finding of 
no significant differences in the presence of other haplotypes of the COMT gene, e.g., 
rs4633, rs6267, rs6270, between individuals with migraine, TTH or healthy people,
17
 
supporting that the COMT rs4680 Val158Met polymorphism seems to be not associated 
to TTH. Nevertheless, since the rs4680 Val158Met polymorphism has been associated, 
in some studies, to conditions such as fibromyalgia syndrome
43 
or temporomandibular 
pain,
44 
it is possible that this genotype may be associated to particular pain conditions 
rather than to chronic pain syndromes in general. Further, since TTH is comorbid with 
other pain syndromes, i.e., fibromyalgia syndrome,
45,46
 we do not know if different 
subgroups of subjects with primary headaches and co-morbid conditions would lead to 
different associations. Finally, the fact that the rs4680 Val158Met polymorphism is not 
associated with TTH does not negate the role of genetics in this headache. For instance, 
some authors have suggested that the 5-HTT-gene-linked polymorphic gene could be 
involved in CTTH.
47 
Therefore, future studies investigating the role of other genetic 
components in TTH are guaranteed. 
rs4680 Val158Met polymorphism and pressure pain sensitivity 
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The most relevant finding of this study is that we found that women with CTTH, 
but not FETTH, carrying the Met/Met genotype exhibited greater pressure sensitivity at 
localized and remote (non-localized) sites, suggesting widespread pressure hyperalgesia 
than those with the Val/Val or Val/Met genotype. These findings would suggest that the 
Val158Met polymorphism could play a role within the nociceptive pain processing in 
CTTH. The association of the rs4680 Val158Met polymorphism with greater pressure 
pain hyperalgesia has been also previously reported in children with CTTH,
18
 breast 
cancer survivors,
19
 and women with fibromyalgia.
48 
Previous studies observed that 
patients with the Met/Met genotype exhibited higher localized, but not widespread, 
pressure pain sensitivity than those with the other genotypes.
18,19
 Our study is the first 
reporting an association between rs4680 Val158Met polymorphism and pressure pain 
sensitivity at localized and remote sites in TTH, particularly the chronic form.  
          Determining the mechanisms involved in the relationship between the Val158Met 
polymorphism and pressure pain hypersensitivity in adults with CTTH are beyond the 
scope of this study; however, a few hypotheses can be proposed. First, a reduction in the 
COMT activity associated with the Met allele at codon 158 of the Val158Met leads to a 
reduction in the content of enkephalins in certain regions of the central nervous system 
associated with pain.
9
 This hypothesis would correlate with the dysfunctional state of 
endogenous inhibitory pain pathways previously observed in adults with CTTH.
49,50 
Another mechanism may be that reduced COMT activity would result in elevated levels 
of catecholamimes, e.g., epinephrine, which promote the production of persistent pain 
states via stimulation of 2-adrenergic receptors in the central nervous system.
51 
Since 
subjects with CTTH have hyper-excitability of the central nervous system, it is possible 
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that the presence of the Met/Met genotype, in predisposed individuals, could contribute 
to central sensitization. This hypothesis has been also suggested for fibromyalgia.
52 
rs4680 Val158Met polymorphism and depressive levels 
We also found that women with CTTH carrying the Met/Met genotype showed 
higher depressive symptoms than women with CTTH carrying the other genotypes, 
suggesting that the rs4680 Val158Met polymorphism can play a potential role in mood 
disorders. In agreement with our results, the Met allele was also associated with greater 
levels of depression in fibromyalgia syndrome women.
20 
A potential neurophysiological 
link between mood disorders and the COMT gene may be the fact that subjects carrying 
the Met/Met genotype exhibit greater brain activation of the limbic region as response 
to emotionally challenging situations.
53,54 
In addition, Met/Met carriers exhibited lower 
activation of the dorso-lateral pre-frontal cortex and cingulate cortex than those Val/Val 
carriers.
55 
Therefore, it is possible that subjects carrying the Met/Met genotype would 
exhibit different cortical activation patterns than those carrying the Val/Val or Val/Met 
genotype. Nevertheless, recent meta-analyses have concluded that the association of the 
Val158Met polymorphism and depression, particularly mayor depressive disorder, is 
more complex than expected and several cofounders, such as gender or ethnicity can be 
present
56,57
 Future studies are needed to determine if the association between the rs4680 
Val158Met polymorphism and depression is related to the pain condition rather than to 
other factors.  
Limitations 
Although the results of this study are promising, we should recognize potential 
limitations. First, we included women with TTH and derived from a specialized tertiary 
hospital center. Therefore, our results should be not extrapolated to men with TTH, and 
to other primary headaches such as migraine. Second, a greater sample size including 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
patients from the general population are now needed to confirm these results. Third, we 
only investigated the rs4680 nucleotide of the Val158Met polymorphism. Future studies 
should include a greater number of nucleotides and other genes to further clarify their 
potential role in the phenotypic expression of TTH. 
Conclusions 
We found no differences in the genotype distribution and allele frequency of the 
rs4680 Val158Met polymorphism between women with FETTH, CTTH, and healthy 
controls. The presence of the Met/Met genotype was associated to higher pressure pain 
hyperalgesia at localized and remote (non-localized) sites and depressive symptoms in 
individuals with CTTH, but not FETTH, suggesting that the Val158Met polymorphism 
may contribute to the altered nociceptive pain processing in CTTH. Future studies are 
needed to further elucidate the relevance of this relationship as a possible contributor to 
the development of CTTH. 
Conflict of Interest Statement 
The Author(s) declare(s) that there is no conflict of interest. 
Author Contributions 
All authors contributed to the study concept and design. CFdlP, SAQ, and MPC 
did the main analysis and interpretation of data. All authors contributed to draft the 
report. AGM, AGP, JAP and LAN provided administrative, technical, and material 
support. LAN supervised the study. All authors revised the text for intellectual content 
and have read and approved the final version of the manuscript. 
Key Findings 
1. This study found that the genotype distribution of the Val158Met polymorphism 
(rs4680) was similar between women with FETTH, CTTH, and healthy controls. 
Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of the article is prohibited.
2. The presence of the Met/Met genotype of the Val158Met polymorphism was 
associated to pressure pain hyperalgesia and depressive symptoms in CTTH, but 
not FETTH. 
3. It is possible that the rs4680 Val158Met polymorphism may contribute to the 
altered nociceptive pain processing in individuals with CTTH.  
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Table 1: Clinical, psychological and psychophysical data of women with 
tension type headache (TTH) and healthy women 
 Frequent Episodic 
TTH (n=50) 
Chronic TTH 
(n=50) 
Healthy 
Control (n=50) 
Age (years) 47 (43-51) 49 (45-53) 48 (44-52) 
Years with pain 7.5 (6.0-9.0) 7.7 (5.7-9.7) ------ 
Headache intensity 
(NPRS, 0-10) 
6.4 (6.0-6.8) 7.1 (6.7-7.5) ------ 
Headache duration 
(hours/attack) * 
7.1 (6.0-8.2) 8.8 (7.7-9.9) ------ 
Headache frequency 
(days/months) *  
9.2 (8.4-10.0) 26.4 (25.6-
27.2) 
------ 
Prophylactic treatment 
(amitriptyline)  
10 (20%) 13 (26%) ------ 
HDI-E (0-52) * 20.4 (17.6-23.2) 26.5 (22.5-
30.5) 
------ 
HDI-P (0-48) * 23.7 (21.2-26.2) 27.9 (24.1-
31.7) 
------ 
PSQI (0-21) 8.1 (7.0-9.2) 9.8 (8.3-11.3) ------ 
HADS-A (0-21) * 13.1 (12.1-14.1) 10.4 (9.1-
11.7) 
------ 
HADS-D (0-21) * 8.3 (7.3-9.3) 10.7 (9.3-
12.1) 
------ 
Pressure Pain Thresholds (kPa) 
Temporalis 
#
 209.2 (190.8-
227.6) 
201.5 (177.8-
225.2) 
275.3 (258.1-
292.5) 
C5-C6 zygapophyseal 
joint 
#
 
184.1 (166.0-
202.2) 
188.8 (169.7-
207.9) 
236.4 (221.3-
251.5) 
Second metacarpal 
#
 274.7 (255.5-
293.9) 
271.0 (240.9-
301.1) 
370.1 (342.7-
397.5) 
Tibialis anterior 
#
 403.5 (361.7-
445.2) 
421.0 (386.8-
455.4) 
518.7 (489.2-
548.2) 
HDI: Headache Disability Inventory (P: Physical, E: Emotional); PSQI: Pittsburgh 
Sleep Quality Index; HADS: Hospital Anxiety and Depression Scale (D: Depression, A: 
Anxiety), 
* Significant differences between frequent episodic and chronic tension type headache 
(student t-test, P<0.05) 
#
 Significant differences between both groups of tension type headache and healthy 
controls (ANOVA test, P<0.001) 
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Table 2: Distribution of the Val158Met Genotypes and Alleles of the 
Catechol-O-Methyltransferase Gene in Women with and without Tension 
Type Headache (TTH) 
 Frequent Episodic 
TTH (n=50) 
Chronic TTH 
(n=50) 
Healthy 
Control (n=50) 
Genotypes 
H/H 
(Val/Val)  
20 (40%) 16 (32%)  21 (42%)  
H/L 
(Val/Met) 
21 (42%)  25 (50%) 19 (38%) 
L/L 
(Met/Met) 
9 (18%) 9 (18%) 10 (20%) 
Alleles 
Val 61 (61%) 57 (57%) 61 (61%) 
Met 39 (39%) 43 (43%) 39 (39%) 
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Table 3: Differences in Headache Clinical Outcomes in Women with 
Tension Type Headache Depending on the Val158Met Polymorphism in 
the Catechol-O-Methyltransferase Gene  
 Years with 
Pain 
Intensity (NPRS, 
0-10) 
Duration 
(hours/attack) 
Frequency 
(days/month) 
Women with the H/H (Val/Val) genotype  
FETTH 
(n=20) 
7.3 (4.3-10.3) 6.6 (5.8-7.4) 7.3 (5.4-9.2) 9.0 (7.7-10.3) 
CTTH 
(n=16) 
7.7 (4.3-11.1) 7.0 (6.2-7.8) 9.1 (8.0-10.2) 26.5 (25.1-27.9) 
Women with the H/L (Val/Met) genotype 
FETTH 
(n=21) 
7.1 (4.1-10.1) 6.4 (5.7-7.1) 6.7 (4.9-8.5) 9.7 (8.4-11.0) 
CTTH 
(n=25) 
7.9 (5.2-10.6) 7.4 (6.7-8.1) 8.6 (7.0-10.2) 26.6 (25.4-27.8) 
Women with the L/L (Met/Met) genotype  
FETTH 
(n=9) 
9.1 (5.5-12.7) 6.8 (5.7-7.9) 7.3 (5.6-9.0) 8.4 (6.4-10.4) 
CTTH 
(n=9) 
7.4 (4.8-10.0) 6.9 (5.8-8.0) 8.7 (6.9-10.5) 25.8 (23.8-27.8) 
 
Values are expressed as mean (95% confidence interval); FETTH: Frequent episodic 
tension type headache; CTTH: Chronic tension type headache  
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Table 4: Differences in Anxiety, Depression, Sleep Quality and Headache 
Burden in Women with Tension Type Headache Depending on the 
Val158Met Polymorphism in the Catechol-O-Methyltransferase Gene  
 HDI-E (0-
52) 
HDI-P (0-
48) 
PSQI (0-21) HADS-A (0-
21) 
HADS-D (0-
21) * 
Women with the H/H (Val/Val) genotype  
FETTH 
(n=20) 
21.4 (15.8-
27.0) 
24.8 (19.7-
29.9) 
8.4 (6.3-10.5) 12.2 (10.5-
13.9) 
8.7 (7.0-10.4) 
CTTH 
(n=16) 
24.8 (18.5-
31.1) 
25.3 (19.6-
31.0) 
8.5 (6.2-10.8) 9.8 (7.9-11.7) 8.3 (6.4-10.2) 
Women with the H/L (Val/Met) genotype  
FETTH 
(n=21) 
19.5 (14.1-
24.9) 
21.4 (16.5-
26.3) 
7.8 (5.7-9.9) 13.3 (11.6-
15.0) 
8.1 (6.5-9.7) 
CTTH 
(n=25) 
27.1 (22.2-
32.0) 
29.2 (24.7-
33.7) 
10.1 (8.3-11.9) 11.5 (9.9-
13.1) 
11.2 (9.6-
12.8) 
Women with the L/L (Met/Met) genotype  
FETTH 
(n=9) 
20.4 (12.2-
28.6) 
26.7 (19.1-
34.3) 
8.4 (6.4-10.4) 14.8 (12.2-
17.4) 
7.6 (6.0-9.2) 
CTTH 
(n=9) 
30.9 (22.6-
39.2) 
31.1 (23.6-
38.6) 
11.6 (8.3-14.9) 8.4 (6.0-10.8) 13.3 (10.8-
15.8) 
 
Values are expressed as mean (95% confidence interval);  
FETTH: Frequent episodic tension type headache; CTTH: Chronic tension type 
headache; HDI: Headache Disability Inventory (P: Physical, E: Emotional); PSQI: 
Pittsburgh Sleep Quality Index; HADS: Hospital Anxiety and Depression Scale (D: 
Depression, A: Anxiety),  
* Significant higher HADS-D score in Met/Met genotype group as compared to Val/Val 
and Val/Met genotypes (2-way ANOVA test) within the CTTH group 
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Table 5: Differences in Pressure Pain Thresholds (kPa) in Women with 
and without Tension Type Headache Depending on the Val158Met 
Polymorphism in the Catechol-O-Methyltransferase Gene  
 
 Temporalis* C5-C6 joint* Second 
metacarpal* 
Tibialis 
anterior* 
Women with the H/H (Val/Val) genotype  
Healthy 
Controls 
(n=21) 
288.2 (258.4-
318.0) 
237.6 (211.1-
264.1) 
375.3 (335.4-
415.2) 
531.9 (477.9-
585.9) 
FETTH (n=20) 220.4 (189.8-
251.0) 
181.1 (153.8-
208.4) 
279.5 (238.6-
320.4) 
396.8 (341.4-
452.2) 
CTTH (n=16) 233.2 (209.0-
257.4) 
202.7 (172.2-
233.2) 
280.8 (245.2-
316.4) 
423.1 (381.2-
465.0) 
Women with the H/L (Val/Met) genotype 
Healthy 
Controls 
(n=19) 
264.4 (233.1-
295.7) 
235.4 (207.5-
263.3) 
364.6 (322.7-
406.5) 
524.2 (467.4-
581.0) 
FETTH (n=21) 202.4 (172.6-
232.2) 
188.2 (161.6-
214.8) 
273.8 (233.9-
313.7) 
411.3 (357.2-
465.4) 
CTTH (n=25) 201.0 (183.7-
218.3) 
196.3 (171.9-
220.7) 
282.6 (246.1-
319.1) 
426.5 (376.9-
476.2) 
Women with the L/L (Met/Met) genotype  
Healthy 
Controls 
(n=10) 
268.6 (225.4-
311.8) 
235.5 (196.9-
274.1) 
369.6 (321.8-
417.4) 
480.3 (422.0-
538.6) 
FETTH (n=9) 200.4 (154.9-
245.9) 
181.4 (150.8-
212.0) 
266.6 (225.7-
307.5) 
400.1 (337.6-
462.6) 
CTTH (n=9) 146.7 (121.2-
172.2) 
143.6 (118.9-
168.3) 
221.3 (190.4-
252.2) 
329.0 (286.5-
371.5) 
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Values are expressed as mean (95% confidence interval); FETTH: Frequent episodic 
tension type headache; CTTH: Chronic tension type headache * Significant lower PPTs 
in Met/Met genotype group as compared to Val/Val and Val/Met genotypes (3-way 
ANOVA test) within the CTTH group 
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